Angiogenesis Inhibition in the Second-Line Treatment of Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis

The last two decades have seen intensive efforts devoted to the development of compounds that target angiogenesis for the treatment of metastatic colorectal cancer (mCRC). In this review, we describe supporting evidence and ongoing development of angiogenesis inhibitors in the second-line treatment of mCRC, and summarize relevant randomized trials to help therapeutic decision-making in daily practice.

Source: Seminars in Oncology - August 2, 2017 Category: Cancer & Oncology Authors: Ralph Chebib, Loic Verlingue, Nathalie Cozic, Matthieu Faron, Pascal Burtin, Val érie Boige, Antoine Hollebecque, David Malka Source Type: research